VIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:VVUS
Previous Symbol
CUSIP92855110
Phone650-934-5200
Debt
Debt-to-Equity RatioN/A
Current Ratio4.36
Quick Ratio3.80
Price-To-Earnings
Trailing P/E Ratio-1.05
Forward P/E Ratio-0.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$65.37 million
Price / Sales0.49
Cash FlowN/A
Price / CashN/A
Book Value($0.88) per share
Price / Book-3.45
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-30,510,000.00
Net Margins-74.75%
Return on EquityN/A
Return on Assets-15.11%
Miscellaneous
Employees52
Outstanding Shares10,630,000
Market Cap$34.12 million
OptionableOptionable
VIVUS (NASDAQ:VVUS) Frequently Asked Questions
What is VIVUS's stock symbol?
VIVUS trades on the NASDAQ under the ticker symbol "VVUS."
When did VIVUS's stock split? How did VIVUS's stock split work?
Shares of VIVUS reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.
How were VIVUS's earnings last quarter?
VIVUS, Inc. (NASDAQ:VVUS) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.11) by $0.24. The biopharmaceutical company had revenue of $18.09 million for the quarter. View VIVUS's Earnings History.
When is VIVUS's next earnings date?
Has VIVUS been receiving favorable news coverage?
News stories about VVUS stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. VIVUS earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of VIVUS's key competitors?
Some companies that are related to VIVUS include Emisphere Technologies (EMIS), Selecta Biosciences (SELB), Sol Gel Technologies (SLGL), Sesen Bio (SESN), Catalyst Biosciences (CBIO), Sierra Oncology (SRRA), Northwest Biotherapeutics (NWBO), Imprimis Pharmaceuticals (IMMY), Adamis Pharmaceuticals (ADMP), Syndax Pharmaceuticals (SNDX), Avadel Pharmaceuticals (AVDL), XOMA (XOMA), Mustang Bio (MBIO), VBI Vaccines (VBIV) and MOTIF BIO PLC/S (MTFB).
Who are VIVUS's key executives?
VIVUS's management team includes the folowing people:
- Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
- Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
- Dr. Santosh T. Varghese, Chief Medical Officer (Age 48)
- Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)
- Mr. John P. Amos, CEO & Director (Age 51)
Who are VIVUS's major shareholders?
VIVUS's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.79%), BlackRock Inc. (1.93%) and Worth Venture Partners LLC (0.28%). Company insiders that own VIVUS stock include Herm Rosenman, John P Amos, Mark K Oki, North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.
Which institutional investors are selling VIVUS stock?
Which institutional investors are buying VIVUS stock?
VVUS stock was acquired by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC. Company insiders that have bought VIVUS stock in the last two years include Herm Rosenman, John P Amos and Mark K Oki. View Insider Buying and Selling for VIVUS.
How do I buy shares of VIVUS?
Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VIVUS's stock price today?
One share of VVUS stock can currently be purchased for approximately $3.07.
How big of a company is VIVUS?
VIVUS has a market capitalization of $34.12 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. VIVUS employs 52 workers across the globe.
What is VIVUS's official website?
How can I contact VIVUS?
VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]
MarketBeat Community Rating for VIVUS (NASDAQ VVUS)
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
